Altimmune’s pemvidutide shows promising Phase IIb MASH results; see key benefits, risks, and a bullish outlook. Read here for ...

Minneapolis Federal Reserve President Neel Kashkari did not support the Fed's interest rate cut last month, he told Bloomberg ...

Read here for an analysis of Boise Cascade (BCC) stock's market resilience, high vertical integration, and financial outlook ...

Kyverna Therapeutics (KYTX) is rated a strong buy with promising KYV-101 Phase 2 data and near-term catalysts. Read here for ...

Pfizer beats Q3 estimates, raises FY guidance, acquires Metsera for obesity drugs, and offers a 7% yield. Read here for an ...

The Fed continues to navigate a challenging backdrop: a steadily cooling labor market alongside inflation that remains ...

The iShares MSCI Chile ETF (ECH) is outperforming emerging markets and showing breakout potential ahead of elections. See ...

Meta Platforms delivers long-term compounding, AI monetization, strong Q3 growth and higher CAPEX with upside potential.

Arch Capital Group shows strong fundamentals, solid Q3 benefits, steady profitability and disciplined buybacks at value ...

ORIX Corp stock is rated a Buy after a strong Q2, a 70% profit surge, and raised FY26 guidance. Here's what investors need to ...

Adam Gould, Global Head of Equities at Tradeweb, said, “Our European ETF platform delivered another strong performance in ...

Sherwin-Williams stock faces premium valuation risks amid muted growth. See why analysts rate SHW a strong sell and what ...